Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
